What is the evidence regarding the safety of new obesity pharmacotherapies
However, real-world data shows conflicting persistence trends, with one study revealing that 63% of patients persist for at least one year, while another shows that one-third of people stopped taking their GLP-1 in the first month, and less than half stayed on for more than 12 weeks
Mutations in the lysyl hydroxylase 1 gene that result in enzyme deficiency and the clinical phenotype of EhlersDanlos syndrome type VI
Lyophilization of peptide therapeutics: stabilizers, mechanisms, and structural integrity preservation
If not, the centre of gravity stays with drugs and diet fundamentals
Specific protocols: keto as an exit ramp from GLP-1 This section provides actionable detail for what many consider the most valuable application of this combination: using keto to maintain results after discontinuing GLP-1 therapy